Erasca (ERAS) EPS (Weighted Average and Diluted) (2021 - 2026)
Erasca posted quarterly EPS (Weighted Average and Diluted) of -$0.6 for Q1 2026, down 445.45% year-on-year from $0.17 in Q1 2025, and down 500.0% on a QoQ basis from -$0.1 in Q4 2025.
Erasca (ERAS) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.6 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 445.45% year-over-year to -$0.6; the trailing twelve-month figure through Mar 2026 stood at -$0.93 (down 55.0% YoY), and the FY2025 full-year result was -$0.44, up 36.23% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.6, down from -$0.1 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.09 in Q4 2024 and bottomed at -$1.09 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.21 (2023), against an average of -$0.27.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) tumbled 2280.0%; it then jumped 82.57% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.09 in 2022, then surged by 82.57% to -$0.19 in 2023, then soared by 52.63% to -$0.09 in 2024, then fell by 11.11% to -$0.1 in 2025, then tumbled by 500.0% to -$0.6 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.6 (Q1 2026), -$0.1 (Q4 2025), and -$0.11 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.60 |
| Dec 31, 2025 | -0.10 |
| Sep 30, 2025 | -0.11 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.11 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.11 |
| Jun 30, 2024 | -0.29 |
| Mar 31, 2024 | -0.23 |
| Dec 31, 2023 | -0.19 |
| Sep 30, 2023 | -0.20 |
| Jun 30, 2023 | -0.21 |
| Mar 31, 2023 | -0.22 |
| Dec 31, 2022 | -1.09 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | -0.30 |
| Mar 31, 2022 | -0.31 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | -0.46 |
| Jun 30, 2021 | -1.20 |